Session » Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Autoimmune Disease Transition, Disease Subsets and Prediction of Flares, Cytokines and Autoantibodies

Meeting: 2014 ACR/ARHP Annual Meeting

Abstract Number: 1604

IFN-γ (Th₁), IL4 (Th₂), and IL5 (Th₂) Are Elevated in Pre-Clinical SLE and Predict Transition to Classified Disease Prior to Appearance of Autoantibodies or Clinical Criteria

Abstract Number: 1605

Elevated Regulatory Mediators and Interferon Gamma Associated Responses, but Not Interferon Alpha, BLyS or IP-10, Accompany High-Titer Anti-Ro Autoantibodies in Asymptomatic Mothers of Children with Neonatal Lupus

Abstract Number: 1606

Profiling a Broad Range of Autoantibodies in Healthy and Systemic Lupus Erythematosis Revealed Autoantibody Patterns Associated with Autoantibody Transition and Disease Activity

Abstract Number: 1607

B Cell and Neutrophil-Related Transcripts Predict and Characterize a Lupus Flare

Abstract Number: 1608

Erythrocyte C4d and Antibodies to Anti-C1q Are Associated with Proteinuria in Lupus Nephritis

Abstract Number: 1609

Dissection of the Type I Interferon Response in Systemic Lupus Erythematosus : Serum IFNα Is Elevated in Lupus Nephritis and Correlates with IFN Score; IFNβ Is Elevated in Mucocutaneous Disease

Abstract Number: 1610

New Autoantigens Associated with Lupus Nephritis

Abstract Number: 1611

Modular Transcriptional Neutrophil Signature As Predictive of Nephritis and of Its Severity in SLE Patients

Abstract Number: 1612

Deficient Repair of DNA Double-Strand Breaks and Increased Apoptosis in Patients with Lupus Nephritis

Abstract Number: 1613

Circulating microRNAs As Candidate Biomarkers of Diagnosis in Systemic Lupus Erythematosus

Abstract Number: 1614

Functional Analysis of Interferon Responsiveness in PBMC from SLE Donors Identifies Subgroups with Higher and Lower Disease Activity

Abstract Number: 1615

MiR-127-3p As a Novel Regulator of Type I Interferon Signaling Pathway in SLE

Abstract Number: 1616

Functional Profiling of PBMC from SLE Patients Versus Healthy Controls Identifies Subgroups with Disease-Associated Dysfunctional Signaling

Abstract Number: 1617

Single Cell Interferon Signatures in Lupus Patient Monocytes Reveal a Differential Impact of Interferon Signaling Between Monocyte Subtypes

Abstract Number: 1618

Suppression of IFN-α Production from Systemic Lupus Erythematosus Immune Complexes Via C1 Complex Enzymatic Properties

Abstract Number: 1619

Interferon Dysregulation in an Academic SLE Cohort Is Associated with Distinct Signaling Differences in Blood Neutrophils Versus PBMCs

Abstract Number: 1620

Antibody to Malondialdehyde-Acetaldehyde Adducts (MAA) As a Potential Biomarker of Inflammation in Systemic Lupus Erythrematosus (SLE)

Abstract Number: 1621

A Shift Towards Trans-Signalling Explains Relatively Low CRP Despite an Active Interleukin-6 (IL-6)/IL-6-Receptor (IL-6R) System in SLE

Abstract Number: 1622

Th1 and Th2 Cytokines Are Associated with Cerebral Atrophy in Systemic Lupus Erythematosus

Abstract Number: 1623

Increased CD95 (Fas) Expression on Naive B Cells Is Associated with a Switch to Double Negative and Plasma Cells in the Peripheral Blood, and Correlates with Disease Activity in Systemic Lupus Erythematosus

Abstract Number: 1624

The Role of B Lymphocyte Stimulator in Monocyte Subpopulation Differentiation in SLE

Abstract Number: 1625

Interferon Stimulates Transglutaminase Activity on Human Monocytes and Their Microparticles

Abstract Number: 1626

Autoantibodies Against High Mobility Group Box 1 (HMGB1) in Patients with SLE

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.